Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6VFO1)

• Drug Name: Pregnenolone Drug Info
• Synonyms: Pregnenolone (schizophrenia); Neurosteroid (schizophrenia), Neuroscience; Pregnenolone (schizophrenia), Neuroscience

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 4	[1] , [2]

• Cross-matching ID:
  PubChem CID: 8955
  ChEBI ID: CHEBI:16581
  CAS Number: CAS 145-13-1
  TTD Drug ID: DM6VFO1
  INTEDE Drug ID: DR1336

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Progesterone	DMUY35B	Premature labour	JB00	Approved	[8]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[9]
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[10]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[11]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[12]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[14]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[8]
Verapamil	DMA7PEW	Hypertension	BA00-BA04	Approved	[15]

Drug(s) Metabolized By Sulfotransferase 2A1 (SULT2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[16]
Abiraterone acetate	DMANBZI	Prostate cancer	2C82.0	Approved	[17]
Vonoprazan	DMCOJPS	Gastro-oesophageal reflux	DA22	Phase 4	[18]
Asp-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[19]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[16]
BCP-13498	DM2BO9W	Anaesthesia	9A78.6	Phase 2	[20]
Daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[16]
Bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[16]
Tetramethylbutylphenol	DMW9CH2	Discovery agent	N.A.	Investigative	[16]
N-nonylphenol	DMH3OUX	Discovery agent	N.A.	Investigative	[16]

Drug(s) Metabolized By Dihydrotestosterone oxidoreductase (HSD3B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[21]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[22]
HE2100	DMCP2KH	Thrombocytopenia	3B64	Discontinued in Phase 1	[23]
17alpha-hydroxypregnenolone	DMT2EPG	Discovery agent	N.A.	Investigative	[5]

Drug(s) Metabolized By Beta-HSD adrenal and gonadal type (HSD3B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[21]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[22]
Norethindrone acetate	DMDGCQP	Menorrhagia	GA20.50	Approved	[24]
17alpha-hydroxypregnenolone	DMT2EPG	Discovery agent	N.A.	Investigative	[5]

Drug(s) Metabolized By Sulfotransferase 2B1 (SULT2B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[6]

Drug(s) Targeting Estrogen-related receptor-alpha (ESRRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rimexolone	DMTAREC	Arthritis	FA20	Approved	[25]
D-5519	DM9FAJM	Asthma	CA23	Phase 3	[26]
Dexamethasone palmitate	DMCMT4V	Choroidal neovascularization	9B76	Phase 1/2	[27]
RPR-106541	DMRGC5B	Asthma	CA23	Discontinued in Phase 2	[28]
Rofleponide	DM6OSPQ	Allergic rhinitis	CA08.0	Discontinued in Phase 2	[29]
AD-121	DMB8XJM	Rheumatoid arthritis	FA20	Discontinued in Phase 1/2	[25]
GW-250495	DMWJZAP	Asthma	CA23	Discontinued in Phase 1	[25]
PLD-177	DMPHUBO	Allergic rhinitis	CA08.0	Terminated	[25]
Steroid hormone conjugates	DMOJM08	Cachexia	MG20	Terminated	[30]
Daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen-related receptor-alpha (ESRRA)	TTPNQAC	ERR1_HUMAN	Agonist	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Beta-HSD adrenal and gonadal type (HSD3B2)	DEN0GVQ	3BHS2_HUMAN	Substrate	[5]
Sulfotransferase 2A1 (SULT2A1)	DE0P6LK	ST2A1_HUMAN	Substrate	[6]
Dihydrotestosterone oxidoreductase (HSD3B1)	DERDQWN	3BHS1_HUMAN	Substrate	[5]
Sulfotransferase 2B1 (SULT2B1)	DEZBN53	ST2B1_HUMAN	Substrate	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2376).
• [2] ClinicalTrials.gov (NCT01409096) Study Using Pregnenolone to Treat Bipolar Depression. U.S. National Institutes of Health.
• [3] Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6.
• [4] Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos. 2008 Feb;36(2):435-41.
• [5] Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem. 2002 Nov 8;277(45):42795-801.
• [6] Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
• [7] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [8] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [9] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [10] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [11] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [12] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [13] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [14] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [15] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [16] Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
• [17] Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
• [18] In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
• [19] Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45(10):887-902.
• [20] Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
• [21] Selective inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer. J Steroid Biochem Mol Biol. 2011 May;125(1-2):57-65.
• [22] Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004 May;38(5):874-81.
• [23] Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
• [24] Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007199)
• [27] Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 2002 Jul 20;360(9328):211-8.
• [28] Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. J Pharmacol Exp Ther. 1999 Aug;290(2):594-602.
• [29] Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60.
• [30] The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998 Oct;49(4):421-32.
• [31] Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.